Jefferies Global Healthcare Conference
Logotype for Astellas Pharma Inc

Astellas Pharma (4503) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Astellas Pharma Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

FY 2026 outlook and profitability

  • Strong Q2 results lifted FY26 revenue guidance by JPY110bn and core operating profit guidance by JPY80bn.

  • Core operating profit margin target of 30% brought forward from FY27 to FY26.

  • More than 85% of revenue comes from outside Japan; the U.S. accounts for almost 45%, with products sold in more than 70 countries.

Growth strategy and capital allocation

  • CSP 2026 targets pipeline-led, self-funded growth toward sustainable growth in the mid-2030s; XTANDI U.S. loss of exclusivity starts next August, followed by Europe and other markets.

  • Plan to double sales of five strategic brands over the next five years; target 30% core operating profit margin after R&D investment of 20% of revenue.

  • Next five-year cumulative operating profit forecast of JPY4.3tn versus JPY3.4tn in the prior five years, despite declining revenue; planned allocations include JPY2tn for R&D, JPY850bn for strategic investments and JPY750bn for dividends.

  • Dividend plan commits to annual increases of JPY2 per share over the next five years; cost optimization targets JPY200bn in annual recurring benefits over the plan period, including JPY40bn in FY26 and JPY45bn in FY27.

  • Business development will prioritize assets that can benefit from existing expertise, often around clinical proof of concept; JPY850bn is secured for strategic investments, averaging JPY100bn per year for BD opportunities.

Pipeline and franchise development

  • Target of JPY1tn in revenue from the internal pipeline by the mid-2030s; plan to start 10+ pivotal or Phase III studies over five years, including five this year and next year.

  • Two additional pivotal ASP2138 studies began in the first half; clinical proof of concept declared for VIR-5500, now ASP6958, and other programs advanced into clinical development.

  • Pipeline strategy builds franchises across prostate cancer, Claudin 18.2 and ophthalmology, linking biology, modality and disease needs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Astellas Pharma